(Press-News.org) Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.
The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor.
Gefitinib is a type of drug known as a tyrosine kinase inhibitor, and it targets cells with EGFR mutations. Most patients with EGFR mutation-positive non-small cell lung cancer respond to first-line EGFR tyrosine kinase inhibitors, but later acquire resistance. The primary objective of the trial was to show whether there was a difference in progression-free survival when gefitinib was continued in this situation.
"This study was designed to resolve a greatly debated issue: whether tyrosine kinase inhibitors should be continued beyond progression," said study author Prof Tony Mok, a professor in the Department of Clinical Oncology at the Chinese University of Hong Kong. "As the result demonstrated no difference in progression-free survival, the standard treatment is chemotherapy alone."
This study helps to establish the standard of treatment, and in the future doctors should not prescribe EGFR tyrosine kinase inhibitors in combination with chemotherapy when cancers have progressed after first-line treatment with an EGFR tyrosine kinase inhibitor, Mok said.
The researchers had hoped that the study would show an improvement in progression-free survival, Mok said. "I suspected the inhibition of TKI-sensitive cancer cells with continuation of gefitinib and inhibition of resistant cells with chemotherapy would optimize the treatment outcome. However, the study has proved otherwise."
The IRESSA Mutation Positive Multicentre Treatment Beyond ProgRESsion Study included 265 patients from 71 centres in Europe and the Asia Pacific region who received chemotherapy plus either gefitinib or a placebo. There was no statistically significant improvement in progression-free survival --the primary endpoint of the study-- for gefitinib versus placebo.
The overall survival data is still immature, Mok said, although there is a suggestion of better overall survival in the placebo group. "This needs to be monitored very closely in future," he said.
Commenting on the study, Dr Marina Garassino, a Medical Consultant at the Medical Oncology Division of the National Cancer Institute of Milan, said the results were "very robust and reliable, and they will help clinicians in their daily clinical practice."
"However, when possible, it is important to re-biopsy the patients when their tumours progress after treatment with tyrosine kinase inhibitors to understand the mechanism that underlies the resistance," Garassino noted.
"New generations of agents are now becoming available for specific resistance mutations with very promising results. It is therefore possible in the future that we will be able to personalise the further treatments for these patients."
INFORMATION:
IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
2014-09-29
ELSE PRESS RELEASES FROM THIS DATE:
Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
2014-09-29
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.
CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically ...
Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
2014-09-29
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.
In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very poor outlook. Only about 20-30% have tumour shrinkage after conventional chemotherapy and survival ...
Many patients lack information about the use of targeted therapies, oncologists say
2014-09-29
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.
The results come from an online survey of 895 doctors from 12 countries in Europe, South America and Asia. All were practicing oncology specialists, with more than three years' experience, treating more than fifteen patients a month.
While 82% of those surveyed believed that deciding on a course of treatment ...
Under-representation of women in oncology leadership positions
2014-09-29
A growing number of oncologists in Greece are female, but women continue to be under-represented in leadership positions, according to a survey reported at the ESMO 2014 Congress.
"In Greece, and across Europe, women oncologists still find it hard to access leadership or academic positions," said Dr Helena Linardou, Associate Director of the 1st Department of Oncology at the Metropolitan Hospital, Athens, Greece, who presented the survey results at the congress.
"Women are indeed increasingly choosing oncology specialties in Greece, however, most decision-making posts ...
Is expressive suppression effective in reducing negative emotion?
2014-09-29
A recent study based on a Chinese sample gives an answer to this question. The research shows that in Chinese culture, emotion- expressive suppression is not only able to dampen negative emotion effectively, but also dampen negative emotion faster than Cognitive reappraisal. This sheds much light on how to quickly regulate negative emotion in urgent situations, particularly when people from East-Asian cultures are concerned.
This study has been published in SCIENCE CHINA： Life Sciences (IN CHINESE) , which is titled "The efficiency of negative emotion regulation: ...
Using the brain to forecast decisions
2014-09-29
You're waiting at a bus stop, expecting the bus to arrive any time. You watch the road. Nothing yet. A little later you start to pace. More time passes. "Maybe there is some problem", you think. Finally, you give up and raise your arm and hail a taxi. Just as you pull away, you glimpse the bus gliding up. Did you have a choice to wait a bit longer? Or was giving up too soon the inevitable and predictable result of a chain of neural events?
In research published on 09/28/2014 in the journal Nature Neuroscience, scientists show that neural recordings can be used to forecast ...
Smart, eco-friendly new battery to solve problems
2014-09-29
Present-day lithium batteries are efficient but involve a range of resource and environmental problems. Using materials from alfalfa (lucerne seed) and pine resin and a clever recycling strategy, Uppsala researchers have now come up with a highly interesting alternative. Their study will be presented soon in the scientific journal ChemSusChem.
'We think our discovery can open several doors to more environment-friendly, energy-efficient solutions for the batteries of the future,' says Daniel Brandell, Associate Professor at the Department of Chemistry, Uppsala University, ...
Protein that causes frontotemporal dementia also implicated in Alzheimer's disease
2014-09-29
SAN FRANCISCO, CA—September 28, 2014—Researchers at the Gladstone Institutes have shown that low levels of the protein progranulin in the brain can increase the formation of amyloid-beta plaques (a hallmark of Alzheimer's disease), cause neuroinflammation, and worsen memory deficits in a mouse model of this condition. Conversely, by using a gene therapy approach to elevate progranulin levels, scientists were able to prevent these abnormalities and block cell death in this model.
Progranulin deficiency is known to cause another neurodegenerative disorder, frontotemporal ...
Predicting landslides with light
2014-09-29
WASHINGTON, Sept. 29, 2014—Optical fiber sensors are used around the world to monitor the condition of difficult-to-access segments of infrastructure—such as the underbellies of bridges, the exterior walls of tunnels, the feet of dams, long pipelines and railways in remote rural areas.
Now, a team of researchers in Italy are expanding the reach of optical fiber sensors "to the hills" by embedding them in shallow trenches within slopes to detect and monitor both large landslides and slow slope movements. The team will present their research at The Optical Society's (OSA) ...
Scientists identify the signature of aging in the brain
2014-09-29
How the brain ages is still largely an open question – in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. The scientists believe that this discovery may lead, in the future, to treatments that can slow or ...